20 Biotech And Pharma Stocks Offering More-Than-Your-Average Upside Potential

More than 10 years into this bull market, Buy and Outperform analyst ratings generally come with implied upside potential of 8% to 10%. However, the author of today’s article notes that “One area of the market that can see much greater upside opportunities, which also implies a greater risk, is the biotech and emerging pharmaceutical stocks” – and he proceeds to highlight 20 biotech and pharma stocks that have seen analyst calls since January 1st that suggest much larger upside potential. For more, CLICK HERE.

Read More

3 Stocks For Post-Halloween “Monster Growth”

Halloween is over and assorted monster costumes have been put away – but there is still monster growth to be had in certain stocks! Today’s article highlights three stocks “with strong monster growth narratives” – each of which has recently reported impressive earnings numbers and had their price targets increased by some of Wall Street’s top-performing analysts as a result. For these three “monster growth” stocks – all of which have “Strong Buy” consensus ratings and upside potential above 20% – CLICK HERE.

Read More